| Literature DB >> 34400351 |
Srimanta Patra1, Prakash P Praharaj1, Daniel J Klionsky2, Sujit K Bhutia3.
Abstract
Histone deacetylases (HDACs) inhibit the acetylation of crucial autophagy genes, thereby deregulating autophagy and autophagic cell death (ACD) and facilitating cancer cell survival. Vorinostat, a broad-spectrum pan-HDAC inhibitor, inhibits the deacetylation of key autophagic markers and thus interferes with ACD. Vorinostat-regulated ACD can have an autophagy-mediated, -associated or -dependent mechanism depending on the involvement of apoptosis. Molecular insights revealed that hyperactivation of the PIK3C3/VPS34-BECN1 complex increases lysosomal disparity and enhances mitophagy. These changes are followed by reduced mitochondrial biogenesis and by secondary signals that enable superactivated, nonselective or bulk autophagy, leading to ACD. Although the evidence is limited, this review focuses on molecular insights into vorinostat-regulated ACD and describes critical concepts for clinical translation.Entities:
Keywords: Autophagy; Cancer; Cell death; Histone deacetylases; Vorinostat
Mesh:
Substances:
Year: 2021 PMID: 34400351 PMCID: PMC8714665 DOI: 10.1016/j.drudis.2021.08.004
Source DB: PubMed Journal: Drug Discov Today ISSN: 1359-6446 Impact factor: 7.851